Core Viewpoint - Berry Genomics (000710.SZ) forecasts a net loss of 170 million to 250 million yuan for the fiscal year 2025, compared to a loss of 192 million yuan in the same period last year [1] Financial Performance - The company's net profit attributable to shareholders is expected to be a loss of 170 million to 250 million yuan, with a non-GAAP net profit loss of 165 million to 245 million yuan, both reflecting a decline from the previous year's loss of 192 million yuan [1] Revenue and Cash Flow - Revenue has declined due to factors such as a decrease in birth rates, although operating cash flow remains stable [1] Asset Management - The company has conducted a comprehensive review and impairment testing of various assets based on the principle of prudence, which has impacted the net profit for the reporting period [1] Research and Development - Berry Genomics has increased its R&D investment and is actively expanding its product lines, leading to enhanced capabilities in third-generation gene sequencing technology, which has also affected the current net profit due to high R&D expenses [1] Strategic Initiatives - The company is focusing on integrating gene testing technology with artificial intelligence algorithms to promote innovation in precision medicine, which has generated some revenue [1] Business Development - The newborn gene screening business is progressing as expected, which is anticipated to have a significant positive impact on the company's business layout in the reproductive health sector [1]